CROs and trial design

Shire links with US hospital for rare disease research
Shire links with US hospital for rare disease research Willwork with Cincinnati Children's Hospital Medical Centre novel therapies
FDA awards $19m in rare disease grants
FDA awards $19m in rare disease grants US regulator supports 15 orphan drug projects
The moving parts of orphan drug development
The moving parts of orphan drug development Tackling rare diseases requires high levels of cooperation, regulatory support and a determination to succeed
Shire boosts rare disease portfolio with $260m Lumena deal
Shire boosts rare disease portfolio with $260m Lumena deal Acquisition of US company will bring two mid-stage candidates for rare liver diseases
Amgen cholesterol antibody shines in rare disease trial
Amgen cholesterol antibody shines in rare disease trial Evolocumab passes late-stage study
WCCT Global talks up orphan drug benefits of new service
WCCT Global talks up orphan drug benefits of new service CRO's In-Site programme will harness digital technology for patient recruitment
Sanofi strikes $700m rare diseases deal
Sanofi strikes $700m rare diseases deal Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs
Novartis myeloma drug clears phase III trial
Novartis myeloma drug clears phase III trial Panobinostat on course to be first in new class of treatment for bone marrow cancer
Shire snaps up Viropharma to build $2bn rare disease unit
Shire snaps up Viropharma to build $2bn rare disease unit Gains access to Cinryze in expensive but 'strategically sound' deal
GSK wins anthrax contract from US government
GSK wins anthrax contract from US government Signs $196m deal for its monoclonal anti-toxin raxibacumab
Result pages: 1 | 2 ()